Nicole K Andeen1, Megan L Troxell2, Maziar Riazy3, Rupali S Avasare4, Jessica Lapasia3, J Ashley Jefferson5, Shreeram Akilesh6, Behzad Najafian6, Roberto F Nicosia6,7, Charles E Alpers6, Kelly D Smith8. 1. Department of Pathology, St. Paul Hospital, University of British Columbia, Vancouver, Canada; andeen@ohsu.edu kelsmith@uw.edu. 2. Division of Nephrology, Department of Medicine, Oregon Health & Science University, Portland Oregon. 3. Nephrology Service Line, The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, California. 4. Department of Pathology and. 5. Division of Nephrology, Department of Medicine. 6. Department of Pathology, University of Washington; and. 7. Seattle Veterans Affairs Medical Center, Seattle, Washington. 8. Department of Pathology, University of Washington; and andeen@ohsu.edu kelsmith@uw.edu.
Abstract
BACKGROUND AND OBJECTIVES: Fibrillary GN has been defined as an immune complex-mediated GN with amyloid-like fibrils larger than amyloid which are IgG positive and Congo red negative. With discovery of DNAJB9 as a highly sensitive and specific marker for fibrillary GN, the specificity of the morphologic criteria for establishing the diagnosis of fibrillary GN has come into question. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We sought to (1) determine anatomic characteristics that best define fibrillary GN and (2) identify clinical and pathologic features that predict outcomes. RESULTS: We retrospectively reviewed kidney biopsies from patients diagnosed with fibrillary GN or suspected fibrillary GN between 1997 and 2017 (n=266, 65% female, median age 61). Approximately 11% of kidney biopsies had one or more unusual feature including monotypic deposits, Congo red positivity, or unusual fibril diameter. Fibrillary GN as a possible monoclonal gammopathy of renal significance represented <1% of cases. Immunostaining for DNAJB9 confirmed fibrillary GN in 100% of cases diagnosed as fibrillary GN and 79% of atypical cases diagnosed as possible fibrillary GN. At a median time of 24 months (interquartile range, 8-46 months) after biopsy (n=100), 53% of patients reached the combined primary outcome of ESKD or death, 18% had CKD, and 18% had partial remission. On multivariable analysis, male sex (adjusted hazard ratio [aHR], 3.82; 95% confidence interval [95% CI], 1.97 to 7.37) and eGFR were the most significant predictors of primary outcome (aHR of 8.02 if eGFR <30 ml/min per 1.73 m2 [95% CI, 1.85 to 34.75]; aHR of 6.44 if eGFR 30 to <45 ml/min per 1.73 m2 [95% CI, 1.38 to 29.99]). Immunosuppressive therapy with rituximab was significantly associated with stabilization of disease progression. CONCLUSIONS: Detection of DNAJB9 is a useful diagnostic tool for diagnosing atypical forms of fibrillary GN. The outcomes for fibrillary GN are poor and progression to ESKD is influenced predominantly by the degree of kidney insufficiency at the time of diagnosis and male sex. Rituximab may help preserve kidney function for select patients with fibrillary GN. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_11_04_CJN03870319.mp3.
BACKGROUND AND OBJECTIVES: Fibrillary GN has been defined as an immune complex-mediated GN with amyloid-like fibrils larger than amyloid which are IgG positive and Congo red negative. With discovery of DNAJB9 as a highly sensitive and specific marker for fibrillary GN, the specificity of the morphologic criteria for establishing the diagnosis of fibrillary GN has come into question. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We sought to (1) determine anatomic characteristics that best define fibrillary GN and (2) identify clinical and pathologic features that predict outcomes. RESULTS: We retrospectively reviewed kidney biopsies from patients diagnosed with fibrillary GN or suspected fibrillary GN between 1997 and 2017 (n=266, 65% female, median age 61). Approximately 11% of kidney biopsies had one or more unusual feature including monotypic deposits, Congo red positivity, or unusual fibril diameter. Fibrillary GN as a possible monoclonal gammopathy of renal significance represented <1% of cases. Immunostaining for DNAJB9 confirmed fibrillary GN in 100% of cases diagnosed as fibrillary GN and 79% of atypical cases diagnosed as possible fibrillary GN. At a median time of 24 months (interquartile range, 8-46 months) after biopsy (n=100), 53% of patients reached the combined primary outcome of ESKD or death, 18% had CKD, and 18% had partial remission. On multivariable analysis, male sex (adjusted hazard ratio [aHR], 3.82; 95% confidence interval [95% CI], 1.97 to 7.37) and eGFR were the most significant predictors of primary outcome (aHR of 8.02 if eGFR <30 ml/min per 1.73 m2 [95% CI, 1.85 to 34.75]; aHR of 6.44 if eGFR 30 to <45 ml/min per 1.73 m2 [95% CI, 1.38 to 29.99]). Immunosuppressive therapy with rituximab was significantly associated with stabilization of disease progression. CONCLUSIONS: Detection of DNAJB9 is a useful diagnostic tool for diagnosing atypical forms of fibrillary GN. The outcomes for fibrillary GN are poor and progression to ESKD is influenced predominantly by the degree of kidney insufficiency at the time of diagnosis and male sex. Rituximab may help preserve kidney function for select patients with fibrillary GN. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_11_04_CJN03870319.mp3.
Authors: Jonathan Hogan; Michaela Restivo; Pietro A Canetta; Leal C Herlitz; Jai Radhakrishnan; Gerald B Appel; Andrew S Bomback Journal: Nephrol Dial Transplant Date: 2014-05-27 Impact factor: 5.992
Authors: Michael Collins; Sankar D Navaneethan; Miriam Chung; James Sloand; Bruce Goldman; Gerald Appel; Brad H Rovin Journal: Am J Kidney Dis Date: 2008-09-27 Impact factor: 8.860
Authors: Mariam P Alexander; Surendra Dasari; Julie A Vrana; Julie Riopel; Anthony M Valeri; Glen S Markowitz; Aviv Hever; Vanesa Bijol; Christopher P Larsen; Lynn D Cornell; Mary E Fidler; Samar M Said; Sanjeev Sethi; Loren Paola Herrera Hernandez; Joseph P Grande; Stephen B Erickson; Fernando C Fervenza; Nelson Leung; Paul J Kurtin; Samih H Nasr Journal: Am J Kidney Dis Date: 2018-06-14 Impact factor: 8.860
Authors: Satoru Kudose; Pietro Canetta; Nicole K Andeen; M Barry Stokes; Ibrahim Batal; Glen S Markowitz; Vivette D D'Agati; Dominick Santoriello Journal: Kidney Int Rep Date: 2021-01-28
Authors: Samar M Said; Alejandro Best Rocha; Anthony M Valeri; Mohamad Sandid; Anhisekh Sinha Ray; Mary E Fidler; Mariam Priya Alexander; Christopher P Larsen; Samih H Nasr Journal: Clin Kidney J Date: 2020-12-05